• Mineralys Therapeutics recently highlighted that positive Phase 3 Launch-HTN data for lorundrostat in uncontrolled hypertension and chronic kidney disease were featured in an oral presentation at the European Meeting on Hypertension and Cardiovascular Protection 2026, following completion of six late-stage trials supporting its efficacy and safety profile.
• The company also confirmed participation in the Jefferies 2026 Global Healthcare Conference, underscoring growing clinical and investor attention on lorundrostat’s potential role in treating hypertension and related cardiorenal conditions.
• We’ll now examine how the Phase 3 Launch-HTN data, especially lorundrostat’s validated aldosterone targeting, may influence Mineralys Therapeutics’ investment narrative.

Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

Mineralys Therapeutics Investment Narrative Recap

To own Mineralys Therapeutics, you need to believe lorundrostat can convert a single drug, loss making biotech into a hypertension focused commercial story, with approval risk and competitive pressure as key watchpoints. The new Phase 3 Launch HTN data and oral slot at ESH 2026 reinforce the clinical package behind the already accepted NDA, but do not materially change the near term PDUFA decision as the central catalyst or the risk that lorundrostat may face a crowded class.

The most relevant recent update alongside this ESH 2026 data is the FDA’s March 2026 acceptance of the lorundrostat NDA, with a December 22, 2026 PDUFA date. That filing formalizes the regulatory clock and frames how investors may view Launch HTN’s six trial dataset and aldosterone targeting in the context of potential label scope, while keeping attention on whether Mineralys can eventually offset ongoing net losses with product revenue if approval is granted.

Yet investors should also weigh the possibility that any delay, unexpected FDA request or safety concern around the December 22, 2026 PDUFA date could...

Mineralys Therapeutics' narrative projects $215.7 million revenue and $23.5 million earnings by 2029. This implies an earnings increase of about $195 million from -$171.4 million today.

Uncover how Mineralys Therapeutics' forecasts yield a $50.88 fair value, a 61% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already projecting about US$388 million of revenue and roughly US$49 million of earnings by 2029, so if you are weighing that view against the risk of a single asset setback or a tougher than expected approval process after these Launch HTN data, it is worth recognizing how far apart reasonable opinions can be and considering how this new information might shift those expectations.

Explore 4 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $48.50!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.